TIL(肿瘤浸润淋巴细胞)与乳腺放疗:国际免疫肿瘤生物标志物工作组展望
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
TIL(肿瘤浸润淋巴细胞)(TILs)是乳腺癌的预后和预测生物标志物。
FRONTIER PAPERS
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
TIL(肿瘤浸润淋巴细胞)(TILs)是乳腺癌的预后和预测生物标志物。
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast C
一个NACT周期后的FDG-PET与组织学反应相关,且与RCB的相关性强于MRI。这些发现支持PET作为治疗反应的早期生物标志物,并值得在更大的免疫治疗时代的试验中验证。
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.
TILs可能预测早期TNBC辅助免疫治疗的获益。这些发现值得验证,并支持在未来试验中采用TILs指导的免疫治疗策略。
Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity.
在390名患有I至III期激素受体阳性/HER2-乳腺癌的患者中,较高数量的TIL(肿瘤浸润淋巴细胞)亚型,无论其具有免疫刺激还是免疫抑制特性,包括调节性T细胞、CD8和非CD8 T细胞,均与8年随访期间改善的无远处疾病生存期和总生存期相关。
Necroptosis triggers inflammatory interferon signatures in patient-derived metastatic breast cancer organoids.
乳腺癌(BC)是全球女性中最常见的癌症类型,也是复发、疾病进展和转移的基础。
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号,增强 CAR-NK 细胞对难治性实体瘤的疗效。
Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge.
在此,我们展示了一项多中心分析,针对来自临床实践和3期试验的3,708例人表皮生长因子受体2阳性(HER2+)或三阴性乳腺癌(TNBC)的切除标本和活检标本的cTILs方法。
Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments.
调节性T(Treg)细胞是肿瘤微环境中常规αβ T细胞的有效免疫抑制剂,但它们如何影响固有样γδ T细胞仍知之甚少。
E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.
浸润性小叶乳腺癌(ILC)表现出特定的间质特征,且高TIL(肿瘤浸润淋巴细胞)含量与患者预后不良相关。
MEMBER ACCOUNT
登录成功会直接打开下一页。